Senti Biosciences, Inc. reported a net loss of $18.1 million for the third quarter of 2025, a decrease from the $28.9 million loss recorded in the same period of 2024. For the nine months ending September 30, 2025, the company’s net loss was $47.0 million, compared to $52.2 million for the same period in the previous year. The company’s total operating expenses for the third quarter were $16.9 million, up from $15.2 million in the prior year, driven primarily by increased research and development costs, which rose to $10.5 million from $8.7 million. General and administrative expenses slightly decreased to $6.4 million from $6.6 million.
Senti's financial position has changed significantly since the end of 2024, with cash and cash equivalents dropping to $12.2 million as of September 30, 2025, down from $48.3 million at the end of the previous year. The company also reported an accumulated deficit of $344.1 million, up from $297.1 million at the end of 2024. The decrease in cash reserves is attributed to ongoing operational losses and increased spending on research and development activities. The company anticipates that it will continue to incur substantial losses as it advances its clinical trials and product development.
In terms of strategic developments, Senti has been actively involved in clinical trials for its lead product candidates, including SENTI-202, which targets blood cancers. The company has also entered into a significant agreement with the California Institute for Regenerative Medicine (CIRM) for a grant of up to $8 million to support the clinical development of SENTI-202. However, the company is facing challenges with GeneFab, a related party, which is currently in default on sublease payments amounting to $4.7 million. This situation has raised concerns about Senti's liquidity and ability to meet its operational obligations.
Operationally, Senti has seen an increase in its employee headcount, reflecting its commitment to expanding its research and development capabilities. The company is focused on enhancing its gene circuit platform technologies, which are designed to create next-generation cell and gene therapies. Despite the challenges, Senti remains optimistic about its future, emphasizing the need for additional funding to support ongoing operations and development activities. The company is actively pursuing various financing options to ensure it can continue its research and development efforts and address its liquidity needs.
Looking ahead, Senti Biosciences acknowledges the substantial doubt regarding its ability to continue as a going concern without raising additional capital. The company is committed to exploring all avenues for funding, including equity sales and potential collaborations, to sustain its operations and advance its product pipeline. The management's ability to secure necessary financing will be critical in determining the company's future trajectory and success in the competitive biotechnology landscape.
About Senti Biosciences, Inc.
Senti Biosciences is a biotech company developing cell and gene therapies using proprietary gene circuit platform technologies. Its focus is on engineering smarter, programmable therapies for cancer and other diseases, primarily through off-the-shelf CAR-NK cell products targeting hematologic and solid tumors. The company emphasizes precision, safety, and control in immunotherapy, leveraging synthetic biology, strategic collaborations, and advanced manufacturing to address unmet medical needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.